157 related articles for article (PubMed ID: 12235184)
1. ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice.
Hinsdale ME; Sullivan PM; Mezdour H; Maeda N
J Lipid Res; 2002 Sep; 43(9):1520-8. PubMed ID: 12235184
[TBL] [Abstract][Full Text] [Related]
2. Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1.
Nakamuta M; Chang BH; Zsigmond E; Kobayashi K; Lei H; Ishida BY; Oka K; Li E; Chan L
J Biol Chem; 1996 Oct; 271(42):25981-8. PubMed ID: 8824235
[TBL] [Abstract][Full Text] [Related]
3. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression.
Nakamuta M; Taniguchi S; Ishida BY; Kobayashi K; Chan L
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):747-55. PubMed ID: 9598833
[TBL] [Abstract][Full Text] [Related]
4. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency.
Ikewaki K; Cain W; Thomas F; Shamburek R; Zech LA; Usher D; Brewer HB; Rader DJ
J Lipid Res; 2004 Jul; 45(7):1302-11. PubMed ID: 15102883
[TBL] [Abstract][Full Text] [Related]
5. Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
Schmitz G; Assmann G; Augustin J; Dirkes-Kersting A; Brennhaüsen B; Karoff C
J Lipid Res; 1985 Mar; 26(3):316-26. PubMed ID: 3989390
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition.
Elam MB; von Wronski MA; Cagen L; Thorngate F; Kumar P; Heimberg M; Wilcox HG
Lipids; 1999 Aug; 34(8):809-16. PubMed ID: 10529091
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
10. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.
Rapp JH; Lespine A; Hamilton RL; Colyvas N; Chaumeton AH; Tweedie-Hardman J; Kotite L; Kunitake ST; Havel RJ; Kane JP
Arterioscler Thromb; 1994 Nov; 14(11):1767-74. PubMed ID: 7947602
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
Campos H; Perlov D; Khoo C; Sacks FM
J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
[TBL] [Abstract][Full Text] [Related]
14. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS
J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
Huang Y; Liu XQ; Rall SC; Mahley RW
J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
[TBL] [Abstract][Full Text] [Related]
16. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.
van Vlijmen BJ; Mensink RP; van 't Hof HB; Offermans RF; Hofker MH; Havekes LM
J Lipid Res; 1998 Jun; 39(6):1181-8. PubMed ID: 9643349
[TBL] [Abstract][Full Text] [Related]
17. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits.
Greeve J; Jona VK; Chowdhury NR; Horwitz MS; Chowdhury JR
J Lipid Res; 1996 Sep; 37(9):2001-17. PubMed ID: 8895066
[TBL] [Abstract][Full Text] [Related]
18. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.
Campos E; Nakajima K; Tanaka A; Havel RJ
J Lipid Res; 1992 Mar; 33(3):369-80. PubMed ID: 1569386
[TBL] [Abstract][Full Text] [Related]
19. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.
Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
J Lipid Res; 2000 Aug; 41(8):1328-38. PubMed ID: 10946021
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of low density lipoprotein receptor eliminates apolipoprotein B100-containing lipoproteins from circulation and markedly prevents early atherogenesis in apolipoprotein E-deficient mice.
Murayama T; Yokode M; Horiuchi H; Yoshida H; Sano H; Kita T
Atherosclerosis; 2000 Dec; 153(2):295-302. PubMed ID: 11164418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
